蛋白酶K市场份额、规模、趋势、行业分析报告，按治疗领域（传染病、糖尿病、肿瘤、心脏病、肾病、自身免疫性疾病、神经病学和其他）；按形式（粉末和液体），按地区；2020-2027年细分预测

报告摘要

2019年，全球蛋白酶K市场价值6120万美元，预计在预测期内复合年增长率为7.5%。蛋白酶K又称蛋白酶K（endo-peptidase），是一种广泛应用于分子生物学领域的丝氨酸蛋白酶。这个enzyme可消化头发中的角蛋白，其广泛的特异性使其在核酸分离或细胞裂解中有用。

蛋白酶K在提取DNA和RNA用于体外诊断中的应用是市场增长的关键因素。蛋白酶K还可应用于诊断市场，如去除核糖核酸酶A、阳离子蛋白和溶菌酶中的内毒素；关于传染性海绵状脑病的朊病毒研究；组织样品中的蛋白质消化；蛋白酶脚印；从细胞中分离线粒体；分析组织膜上的酶定位；抗体标记；原位杂交过程中核酸酶的去除；以及聚合酶链反应纯化目的。蛋白酶K也用于区分朊病毒和蛋白酶抗性蛋白。

了解有关此报告的更多信息：样本页请求

However, the substitutes in the market in the form of biocatalyst developed scientifically by the companies is restricting proteinase K market growth. For instance, Biocatalysts Ltd, the UK-based company, in collaboration with Brain AG introduced Proteocut K, a subtilisin type serine protease with higher specificity to hydrolyze proteins, being marketed as an alternative to the liquid form Proteinase K.

Proteocut K and the Proteinase K performance was assessed in an independent lab. Apart from typical nucleic acid separations, Proteocut K was also useful in plasmid DNA extraction, and the de-activation of restriction enzymes. Moreover, Proteocut K has much more resistance to additives and detergents with higher in-activation temperature of 80°C. Although, the launched substitute provides biotechnology, research & development organizations an alternative choice, to source their key raw material for the day-to-day applications across the market.

Industry Dynamics

Growth Drivers
应用程序检测蛋白酶K的procedure of COVID-19 is projected to provide new growth avenues for the global market. The detection through the use of RT-qPCR has gained momentum to control the spread of COVID-19 pandemic. PCR is also considered as gold standard in the detection of infectious diseases, which is likely to drive proteinase K demand.

However, this has certain limitations, to scale up COVID-19 tests in the resource limited settings, where there is shortage of trained professionals with limited market funding. Thus, professionals seeking desired protocols, which enhances the accuracy of the test results apart from assistance in expansion of COVID-19 testing facilities.

According to the study in May 2020, in Brazil, protocol was designed to detect COVID-19 infections without extracting RNA, with the use of samples pre-treated with proteinase K. With this study, it was concluded that, the use of proteinase K, serves the purpose and it is one of the efficient techniques in the diagnosis of COVID-19, without performing time consuming standard protocols. Moreover, the procedure has an efficiency rate of over 90%.

Proteinase K Market Report Scope

市场主要根据治疗领域、形式和区域进行细分。

By Therapeutic Area	按形式	按地区
Infectious diseases Diabetes 肿瘤科 Cardiology 肾病科 Autoimmune diseases Neurology Others	粉末 液体	北美（美国、加拿大） 欧洲（法国、德国、英国、西班牙、荷兰、奥地利） Asia Pacific (Japan, China, India, Malaysia, Indonesia. South Korea) 拉丁美洲（巴西、墨西哥、阿根廷） MEA（沙特阿拉伯、阿联酋、以色列、南非）

了解有关此报告的更多信息：样本页请求

治疗领域的洞察力

根据治疗领域，全球蛋白酶K市场分为传染病、糖尿病、肿瘤、心脏病、肾病、自身免疫性疾病、神经病学和其他。2019年，传染病部门在全球市场中占据最大份额，预计将继续占据主导地位。这一领域的高收入份额归因于蛋白酶K在大多数感染菌株诊断中的适用性及其在核酸分离中的应用。

Numerous research studies have shown extraction of DNA from Hepatitis B virus with proteinase K, results in better isolation of Hepatitis viral genome, which in turn, serves as an efficient procedure in isolating DNA in aqueous phase. Neurology segment is expected to exhibit the fastest growth rate over the forecast period. This high growth is due to its application in prion diagnosis. Proteinase K is currently being served as a substituent to trypsin for the cross-linking studies. The enzyme is also used for sample treatment in the Enzyme-linked Immuno-spot assay to detect prions.

Insight by Form

Based on the form, the global market is bifurcated as powder, and liquid. In 2019, the powered formulation accounted for the largest market share in terms of revenue. The preparation of stock solutions based on protocol requirements for the future purpose is key factor of its high usage. These kinds of enzymes available in the market are subject to denaturation, oxidation, and autolytic degradation processes, which are often supported with water softening substances.

此外，粉末形式克服了一些挑战，如酶的物理分离，也有较长的保质期。物理分离酶是困难的液体形式，因为它是脆弱的有害影响，任何溶剂或任何其他有害影响。例如，氯化钙和羧酸盐的组合可以保护蛋白酶K免受任何降解。

Geographic Overview

2019年，北美市场的收入份额最大。导致这种增长的地区因素包括下一代测序（NGS）、聚合酶链反应和其他测序技术的使用增加。作为这些应用的重要组成部分，蛋白酶K和其他试剂在市场上的应用必将增加。由美国国家人类基因组研究所（National Human Genome Research Institute）发起的新生儿基因组医学与公共卫生（NSIGHT）项目等政府资助的举措，引入了一个美国中央政府资助的项目，以筛查患有遗传病的婴儿，也促进了NGS级蛋白酶K的大量使用。

最近美国市场上COVID-19的激增也补充了蛋白酶K的消费。与此相一致，耶鲁大学公共学院的研究人员在2020年8月获得了美国FDA的紧急使用授权，这是一种昂贵的10美元唾液基COVID-19测试唾液，适用于大量无症状的美国人群。本试验使用蛋白酶K检测样本中是否存在SARS-CoV-2病毒颗粒。

亚太市场预计将出现最高增长率，原因是目标障碍激增，人口基数较高。此外，该地区COVID-19病例的快速激增也补充了对蛋白酶K的需求。截至2020年9月，亚太市场占COVID-19病例的30%以上。这就预示了蛋白酶K在COVID-19和癌症标本分析中的应用。

竞争洞察力

The prominent players operating in the market are Merck KGaA, BBI Solutions, Codexis, Inc., SBS Genetech Ltd. F. Hoffmann-La Roche Ltd, Amicogen, Amano Enzyme Inc., Advanced Enzymes Technologies Ltd, Biocatalysts Ltd, Dyadic International, Affymetrix, and American Laboratories.